HomeAI · summaries
Storia in 3 fonti
Prime Medicine wins spat with Beam Therapeutics over AATD candidate
Prime Medicine wins arbitration vs Beam Therapeutics, plans FDA IND filing for genetic liver disease treatment. $PRME stock rises 12%.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene-editing companies against each other.
- ·
benzinga.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Beam Therapeutics (NASDAQ
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.
